Uppsala University Hospital and Sana Biotechnology Announce Authorization of the First-in-Human Clinical Trial Application for a Primary Islet Cell Treatment for Patients with Type 1 Diabetes
November 17, 2023 09:00 ET
|
Sana Biotechnology, Inc
Goal is to report UP421 proof of concept data in 2023 and 2024 Potential to remove immunosuppression from islet cell transplantation SEATTLE, Nov. 17, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology,...
Sana Biotechnology Announces FDA Clearance of Investigational New Drug Application for SC291, a Hypoimmune-modified, CD19-directed Allogeneic CAR T Therapy, for Patients with Lupus Nephritis, Extrarenal Lupus, and ANCA-associated Vasculitis
November 09, 2023 16:05 ET
|
Sana Biotechnology, Inc
Phase 1 trial to investigate multiple B-cell mediated autoimmune diseases First healthy donor-derived allogeneic CAR T cell therapy to announce IND clearance Expect to disclose initial clinical...
Sana Biotechnology Reports Third Quarter 2023 Financial Results and Business Updates
November 08, 2023 16:05 ET
|
Sana Biotechnology, Inc
Enrolling Phase 1 ARDENT trial investigating SC291 in patients with refractory B-cell malignancies with initial data expected in 2023 and more robust data in 2024 CTA submitted for...
Sana Biotechnology Announces Five Presentations at the 65th American Society of Hematology Annual Meeting
November 02, 2023 09:05 ET
|
Sana Biotechnology, Inc
SEATTLE, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that five...
Sana Biotechnology Announces Increased Focus on Hypoimmune-Related Pipeline with the Potential to Deliver Clinical Proof of Concept Data from Four Programs in 2023 and 2024 with a 2024 Operating Burn under $200M
October 10, 2023 16:15 ET
|
Sana Biotechnology, Inc
Increasing focus on ex vivo cell therapy platform based on extensive preclinical and early translational clinical data suggesting ability of hypoimmune (HIP)-modified cells to evade immune detection ...
Sana Biotechnology to Present at September 2023 Investor Conferences
August 30, 2023 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, Aug. 30, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will...
Sana Biotechnology Reports Second Quarter 2023 Financial Results and Business Updates
August 03, 2023 16:05 ET
|
Sana Biotechnology, Inc
Enrolling patients in ARDENT, the SC291 Phase 1 clinical trial in B-cell malignancies, with initial data expected this year Expect data later this year from investigator-sponsored trial with...
Sana Biotechnology Highlights Preclinical Data from Hypoimmune and Fusogen Platforms at the International Society for Stem Cell Research (ISSCR) 2023 Annual Meeting
June 16, 2023 09:00 ET
|
Sana Biotechnology, Inc
Hypoimmune (HIP)-modified CD19-directed CAR T cells have the potential to serve as a universal off-the-shelf therapy that provides long-term durability of response without immunosuppression ...
Sana Biotechnology to Present at June 2023 Investor Conferences
May 31, 2023 16:05 ET
|
Sana Biotechnology, Inc
SEATTLE, May 31, 2023 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ: SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will...
Sana Biotechnology Announces Preclinical Data Published in Nature Biotechnology Demonstrating its Hypoimmune-Engineered Cells Escape Immune Detection and Survive While Remaining Fully Functional
May 08, 2023 16:35 ET
|
Sana Biotechnology, Inc
Hypoimmune-modified allogeneic iPSCs evade immune response and rejection without immunosuppression in non-human primate model Long-term survival and immune evasion of hypoimmune-modified allogeneic...